Results 141 to 150 of about 3,889 (160)
Some of the next articles are maybe not open access.
Immune-mediated necrotizing myopathy: clinical features and pathogenesis
Nature Reviews Rheumatology, 2020Immune-mediated necrotizing myopathy (IMNM) is a group of inflammatory myopathies that was distinguished from polymyositis in 2004. Most IMNMs are associated with anti-signal recognition particle (anti-SRP) or anti-3-hydroxy-3-methylglutaryl-coA reductase (anti-HMGCR) myositis-specific autoantibodies, although ~20% of patients with IMNM remain ...
Allenbach, Yves +3 more
openaire +3 more sources
HLA-DRB1 alleles in immune-mediated necrotizing myopathy
Neurology, 2016Immune-mediated necrotizing myopathy (IMNM), also known as necrotizing autoimmune myopathy, is a histologic entity characterized by marked necrosis in the absence of prominent lymphocytes.1 Risk factors or triggers for IMNM include statin treatment, cancer, and connective tissue disease (CTD).1,2 Although autoantibodies against signal recognition ...
Yuko, Ohnuki +11 more
openaire +2 more sources
[Immune-Mediated Necrotizing Myopathy(IMNM)].
Brain and nerve = Shinkei kenkyu no shinpo, 2021Immune-mediated necrotizing myopathy (IMNM) has recently been classified from polymyositis, and it clinically shows subacute progressive proximal dominant muscle weakness. Laboratory examinations show a great increase in serum creatine kinase and prominent necrotic muscle fibers without any pathological invasion of inflammatory cells.
openaire +2 more sources
Immune-Mediated Necrotizing Myopathies: Current Landscape
Current Neurology and Neuroscience ReportsImmune-mediated necrotizing myopathy (IMNM), characterized by acute or subacute onset, severe weakness, and elevated creatine kinase levels, poses diagnostic and therapeutic challenges. This article provides a succinct overview of IMNM, including clinical features, diagnostic strategies, and treatment approaches.Recent insights highlight the different ...
Christoforos, Koumas +1 more
openaire +2 more sources
Updates in the Management of Immune-Mediated Necrotizing Myopathy
Rheumatic Disease Clinics of North AmericaWhile the treatment landscape of immune-mediated necrotizing myopathy continues to advance, current approaches still rely heavily on expert consensus, given a lack of robust clinical trial data. A deeper understanding of immunopathogenesis remains essential for more effective treatments.
Suur, Biliciler, Eleni, Tiniakou
openaire +2 more sources
Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management
Current Rheumatology Reports, 2015The idiopathic inflammatory myopathies (IIMs) comprise a group of autoimmune disorders that target skeletal muscle. They are characterized by typical laboratory and clinical features including muscle weakness, elevated muscle enzymes, characteristic histopathology of muscle biopsies, as well as electromyography abnormalities.
Pari, Basharat, Lisa, Christopher-Stine
openaire +2 more sources
Immune-mediated necrotizing myopathy with pembrolizumab: a specific neuromuscular entity
European Journal of Clinical Pharmacology, 2022Pembrolizumab is a humanized monoclonal antibody that binds to the programmed cell-death protein-1 (PD-1) on immune T-cells, thus blocking PD-1 activity. Pembrolizumab is indicated for the treatment of advanced melanoma, metastatic non-small-cell lung cancer, and head and neck squamous cell carcinoma.
Thierry Trenque +4 more
openaire +2 more sources
Immune-Mediated Necrotizing Myopathy (IMNM)
2019Immune-mediated necrotizing myopathy (IMNM) is a distinct subset of the idiopathic inflammatory myopathies, characterized by proximal muscle weakness and muscle atrophy, markedly elevated CK levels, and myocyte necrosis with minimal inflammatory infiltrate on muscle biopsy.
Brittany Adler, Lisa Christopher-Stine
openaire +1 more source
<p>Immune-Mediated Necrotizing Myopathy Initially Presenting as Erythema Nodosum</p>
Journal of Inflammation Research, 2020Sheng Li, Shunli Tang, Qingmiao Sun
exaly